Cheng, Feifei http://orcid.org/0000-0002-3234-513X
Wang, Xuejuan http://orcid.org/0000-0003-4639-7640
Chiou, Yi-Shiou http://orcid.org/0000-0002-0436-6603
He, Chuyu http://orcid.org/0000-0001-6232-4594
Guo, Hui http://orcid.org/0000-0002-2054-3876
Tan, Yan Qin http://orcid.org/0000-0001-7769-2023
Basappa, Basappa http://orcid.org/0000-0002-8844-468X
Zhu, Tao http://orcid.org/0000-0003-4130-1144
Pandey, Vijay
Lobie, Peter E. http://orcid.org/0000-0002-8445-184X
Article History
Received: 24 October 2021
Revised: 10 February 2022
Accepted: 1 March 2022
First Online: 25 March 2022
Competing interests
: Peter E. Lobie and Tao Zhu have previously consulted for Perseis Therapeutics Ltd. Peter E. Lobie are named on PCT application numbers WO 2006/69253 and WO 2008/042435 and US provisional application number 61/059558 and derivatives thereof. Vijay Pandey, Basappa, and Peter E. Lobie are named as inventors on PCT application WO/2018/226155 (PCT/SG2018/050277), Compounds, As Inhibitors of TFF3 Dimerization, Methods and Applications Thereof (and derivatives thereof including US Patent 11,141,402). Peter E. Lobie is an equity holder in Sinotar Pharmaceuticals Ltd which currently holds PCT/SG2018/050277 and derivatives thereof including issued US Patent no. 11,141,402.
: Consent for the use of the tissue samples and clinical data was obtained by Outdo Bio-Tech Co., Ltd. (Shanghai, China). All animal experiments were approved by the Institutional Animal Care and Use Committee of the Laboratory Animal Centre of Peking University Shenzhen Graduate School (YW) and the Ethics Committee of Tsinghua Shenzhen International Graduate School (Ethical Development no. 37, year 2019).
: All of the study participants have given consent to publish this paper.